TNF and Parkinson disease: In our previous study, we investigated in de novo PD patients salivary biomarkers targeting different molecular pathways, including alpha‐synuclein (a‐syn), tau pathology, autophagy (MAPLC3beta), and inflammation (TNFalpha).